Replies to post #254416 on Innovation Pharmaceuticals Inc (IPIX)

[PlentyParanoid]

Karin, you may be right. Last few PR:s (while being 'minor') have had the feel of responses to concerns raised by negotiation partner.
- IPIX has extended brilacidin patent protection with new 'method' patents.
- According to recent studies RT plus cisplatin every 3 weeks will stay the de facto standard of care in HNC.
- Stability of Brilacidin in simulated gastric environment shows that formulation of Brilacidin for oral treatment of IBD will not be a major obstacle.

At the very least IPIX seems to be addressing an audience beyond plain investors like us. As ffrol has often pointed out revelations like brilacidin is stable in gastric acid is nice to know but at this stage it will not move share price. However, it probably is important for a potential partner. Hopefully the effort will yield results.

[seek the light]

Thanks, Karin....So do I and i Also thinks he is much more capable than those who are daily criticizing him.

[farrell90]

I agree. And, contrary to a number of posts on the board IMO it is in Mr Ehrlich's and IPIX's interest to sign the best deal available as soon as possible which {again IMO} will occur "shortly".

IMO the Brillacidin OM was IPIX's best vehicle to the quickest partnership deal.The deal should provide the financing to complete the FDA studies of the other possible applications.

The greatest potential value is not in Oral Mucositis but the other possible Brilacidin indications: Absssi,Sepsis, Ulcerative colitis, Crohn's disease, Irritable bowel syndrome, Sinusitis, acne , eczema, Hidradenitis Suppurativa, diabetic skin ulcers, pressure ulcers, ophthalmic and otic infections.

The value of the other indications is while I am stil here.

Disclaimer: All the above is IMO only and may be completely wrong. Each investor needs to do their own DD and make their own investing decisions.

GLTA, Farrell